|Videos|June 6, 2017

Frontline Bostunib vs Imatinib in Chronic Myeloid Leukemia

Author(s)Jorge E. Cortes, MD

This video highlights results of the BFORE trial, which tested bosutinib vs imatinib in newly diagnosed chronic myeloid leukemia patients.

In this video, Jorge E. Cortes, MD, of the University of Texas MD Anderson Cancer Center in Houston, discusses results of the BFORE trial, which tested bosutinib vs imatinib in newly diagnosed chronic myeloid leukemia patients.

Cortes presented the results of the study (abstract 7002) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.

September 25th, 2026

Targeted Agents, Amyloidosis, and Defining a Cure in Plasma Cell Disorders

“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.

Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.

September 24th, 2026

Anselamimab’s Kappa Subgroup Signal Could Reshape Anti-Fibril Therapy in AL Amyloidosis

Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.

Meletios A. Dimopoulos, MD, discussed where bispecific antibodies such as teclistamab may fit for patients with relapsed Waldenström macroglobulinemia.

September 23rd, 2026

Defining the Role of Bispecifics in Relapsed Waldenström Macroglobulinemia

Meletios A. Dimopoulos, MD, discussed where bispecific antibodies such as teclistamab may fit for patients with relapsed Waldenström macroglobulinemia.

$An end-of-phase 1 meeting was supported by phase 1b data showing efficacy with LYT-220 among relapsed/refractory myelodysplastic syndrome groups.$

September 22nd, 2026

Novel Monoclonal Antibody Wins FDA Fast Track Designation in High-Risk MDS

An end-of-phase 1 meeting was supported by phase 1b data showing efficacy with LYT-220 among relapsed/refractory myelodysplastic syndrome groups.

The updated NCCN Guidelines for myeloproliferative neoplasms recommend rusfertide as a category 1 option across both low- and high-risk polycythemia vera.

September 22nd, 2026

Rusfertide Earns Category 1 NCCN Recommendation in Polycythemia Vera

The updated NCCN guidelines for myeloproliferative neoplasms recommend rusfertide as a Category 1 option across both low- and high-risk polycythemia vera.

Jasmine Zain, MD, described how pre-existing CHIP mutations should inform pre-infusion risk counseling and treatment selection.

September 19th, 2026

Screening for CHIP Mutations to Guide CAR T-Cell Candidacy in Lymphoma

Jasmine Zain, MD, described how preexisting CHIP mutations should inform preinfusion risk counseling and treatment selection.

"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.

September 18th, 2026

Fixed-Duration Combinations and MRD-Guided Therapy as Emerging Priorities in CLL

"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.

Jasmine Zain, MD, described the molecular workup to determine whether a secondary malignancy after CAR T-cell therapy reflects direct insertional mutagenesis.

September 17th, 2026

Differentiating Mutagenesis From Genotoxic Risk in Secondary Malignancies

Jasmine Zain, MD, described the molecular workup to determine whether a secondary malignancy after CAR T-cell therapy reflects direct insertional mutagenesis.

Trending on CancerNetwork

Subcutaneous Pembrolizumab Approved in Japan for All Tumor Indications

Acting on a HER2 Result and Navigating Access to Therapy

The Case for Frontline Zongertinib in HER2-Mutant NSCLC

Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC

Patient-Centered Treatment Transitions in HR+/HER2− mBC